🔥🐔 BizChicken 🐔🔥

Companies Similar to Atossa Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Applied Therapeutics, Inc.

Applied Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

AT-007

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.

Tags: biopharmaceutical, cardiovascular disease, clinical trials, diabetic complications, galactosemia

Symbol: APLT

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shoshana Shendelman Ph.D.

Sector: Healthcare

Employees: 31

Address: 545 Fifth Avenue, New York, NY 10017

Phone: 212 220 9226

Leadership

  • Shoshana Shendelman, Chair, Board of Directors
  • Riccardo Perfetti, Chief Medical Officer
  • Les Funtleyder,
  • Dale Hooks, Chief Commercial Officer
  • Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
  • Joel Marcus,
  • Jay Skyler,
  • Stacy Kanter,
  • Teena Lerner,
  • Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
  • Roy Freeman M.D.,
  • Roxana Mehran M.D.,
  • Lawrence Steinman M.D.,
  • Gregg Stone M.D.,
  • Donald d'Amico M.D.,
  • Donald Landry, Chair, Scientific Advisory Board
  • Roy Freeman,
  • Roxana Mehran,
  • Lawrence Steinman,
  • Gregg Stone,
  • Donald d'Amico,

Last updated: 2024-12-31

Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

AT-527

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a lead product candidate AT-527 for COVID-19 treatment.

Tags: COVID-19, antiviral, biopharmaceutical, clinical-stage, therapeutics

Symbol: AVIR

Recent Price: $3.33

Industry: Biotechnology

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

Sector: Healthcare

Employees: 75

Address: 125 Summer Street, Boston, MA 02110

Phone: 857 284 8891

Leadership

  • Jean-Pierre Sommadossi, PhD, FOUNDER, CHAIRMAN & CEO
  • Nancy Agrawal, PhD, Executive VP, Preclinical Development
  • Jonae Barnes, Senior VP, Investor Relations & Corporate Communications
  • Bruce Belanger, PhD, Senior VP, Biostatistics
  • Andrea Corcoran, CFO & Executive VP, Legal
  • Adam DeZure, MD, VP, Clinical Development
  • James MB Evans, PhD, VP, CMC Manufacturing
  • Wayne Foster, EXECUTIVE VP, Chief Accounting Officer
  • Kerry Gagnon, VP, Head of Quality
  • Steven Good, EXECUTIVE VP, PRECLINICAL SCIENCE
  • Janet Hammond, MD, PhD, CHIEF DEVELOPMENT OFFICER
  • Arantxa Horga, MD, Chief Medical Officer
  • Qi Huang, Senior VP, Virology
  • Laura Ishak, Senior VP, Clinical Operations
  • Ariyapadi Krishnaraj, VP, Marketing
  • Adel Moussa, PhD, EXECUTIVE VP, CHEMISTRY
  • Shari Noble, VP, Deputy General Counsel
  • Keith Pietropaolo, Executive VP, Clinical Sciences and Project Management
  • Brian Rowe, VP, Business Development
  • Marc Van Hulle, VP, Finance
  • John Vavricka, CHIEF COMMERCIAL OFFICER
  • Alex Vo, PhD, VP, DMPK
  • Jayanthi Wolf, PhD, Executive VP, Regulatory Affairs
  • Xiao-Jian Zhou, PhD, EXECUTIVE VP, EARLY STAGE DEVELOPMENT

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

PYX-106, PYX-102, PYX-201, PYX-202, PYX-203

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.

Tags: antibody drug conjugate, biopharmaceutical, cancer therapy, immune-oncology, solid tumors

Symbol: PYXS

Recent Price: $1.56

Industry: Biotechnology

CEO: Dr. Lara S. Sullivan M.D., MBA

Sector: Healthcare

Employees: 55

Address: 35 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 221 9059

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Endoxifen

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.

Tags: COVID-19, Endoxifen, biopharmaceutical, breast cancer, infectious diseases, oncology

Symbol: ATOS

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.

Sector: Healthcare

Employees: 12

Address: 107 Spring Street, Seattle, WA 98104

Phone: 206 588 0256

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

STAR-0215

Astria Therapeutics, Inc., is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases in the United States. Its lead product candidate, STAR-0215, is targeting hereditary angioedema.

Tags: allergic diseases, biopharmaceutical, hereditary angioedema, immunological diseases, rare diseases

Symbol: ATXS

Recent Price: $8.88

Industry: Biotechnology

CEO: Ms. Jill C. Milne Ph.D.

Sector: Healthcare

Employees: 59

Address: 100 High Street, Boston, MA 02110

Phone: 617 349 1971

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

inupadenant, EOS-448

Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.

Tags: biopharmaceutical, clinical trials, immuno-oncology, therapeutics

Symbol: ITOS

Recent Price: $7.29

Industry: Biotechnology

CEO: Dr. Michel Detheux Ph.D.

Sector: Healthcare

Employees: 157

Address: 321 Arsenal Street, Cambridge, MA 02472-5710

Phone: 339 217 0161

Leadership

  • Michel DETHEUX, President, Chief Executive Officer
  • Matt CALL, Chief Operating Officer
  • Matthew GALL, Chief Financial Officer
  • Yvonne MCGRATH, Chief Scientific Officer
  • David Feltquate, Chief Medical Officer
  • Philippe BRANTEGEM, Executive Vice President of Human Resources
  • Adi OSOVSKY, Executive Vice President of Legal
  • David HALLAL, Chair of the Board
  • Aaron DAVIS,
  • Jill DESIMONE,
  • David LEE,
  • Tim VAN HAUWERMEIREN,
  • Tony HO,
  • Robert IANNONE,
  • Ann RHOADS,

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Omega Therapeutics, Inc.

Omega Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

OMEGA Epigenomic Programming platform

Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.

Tags: biopharmaceutical, chronic liver diseases, corneal regeneration, epigenetics, gene control, idiopathic pulmonary fibrosis

Symbol: OMGA

Recent Price: $0.80

Industry: Biotechnology

CEO: Mr. Mahesh Karande

Sector: Healthcare

Employees: 93

Address: 20 Acorn Park Drive, Cambridge, MA 02140

Phone: 617 949 4360

Leadership

  • Mahesh Karande, President & Chief Executive Officer
  • Kaan Certel, Ph.D., Chief Business Officer
  • Jennifer Nelson, Ph.D., Senior Vice President, Research
  • Tony Mullin, Chief People Officer
  • Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
  • Lisamarie Fahy, Senior Vice President, Clinical Development Operations
  • Joe Newman, Ph.D., Senior Vice President, Early Discovery
  • Jeff Atkinson, Ph.D., Vice President, Technical Operations
  • Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs

Last updated: 2024-12-31

Verastem, Inc.

Verastem, Inc. logo
Market Cap: Low
Employees: Low

VS-6766

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for cancer treatment, with products such as VS-6766 and trials like RAMP 201 and 202 targeting various cancer types.

Tags: MEK, RAF, RAMP 201, RAMP 202, VS-6766, biopharmaceutical, cancer treatment, drug development

Symbol: VSTM

Recent Price: $3.67

Industry: Biotechnology

CEO: Mr. Daniel W. Paterson

Sector: Healthcare

Employees: 73

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 781 292 4200

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31